February 9, 2017
Forward Pharma cashes in Biogen’s $1.25 billion
Forward Pharma has received $ 1.25 billion due to the settlement with Biogen’s subsidiaries, it made in January.
Pharmaceuticals, Biotechnology and Life Sciences
Forward Pharma has received $ 1.25 billion due to the settlement with Biogen’s subsidiaries, it made in January.
Danish biopharmaceutical company, Forward Pharma, has entered a deal with Biogen and certain other parties, regarding a Settlement and License Agreement.
Biogen’s Board of Directors has appointed Michel Vounatsos as Chief Executive Officer and member of the Board of Directors, effective…